Target intelligence / Profile preview

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC)

Target
ATIC
Molecular classification
Enzyme, Bifunctional enzyme, Transferase, Hydrolase
01

Overview

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) is a homodimeric, bifunctional enzyme that catalyzes the final two steps of the de novo purine biosynthetic pathway. The C-terminal domain of ATIC possesses phosphoribosylaminoimidazolecarboxamide formyltransferase (AICAR transformylase) activity, which transfers a formyl group to AICAR to produce FAICAR, while the N-terminal domain exhibits IMP cyclohydrolase activity, cyclizing FAICAR to inosine monophosphate (IMP). Because rapidly proliferating cells rely heavily on de novo purine synthesis for DNA and RNA replication, ATIC is highly expressed in various cancers, including lung adenocarcinoma and hepatocellular carcinoma, making it an attractive oncology target. Additionally, genetic deficiency in ATIC leads to AICA-ribosiduria, a rare, neurologically devastating metabolic disorder characterized by the accumulation of AICAR (ZMP) and its excretion as AICA-riboside. Clinically, ATIC is targeted by antifolate chemotherapeutics and anti-inflammatory agents such as pemetrexed and methotrexate. Inhibition of ATIC leads to the accumulation of intracellular ZMP, an AMP analogue that allosterically activates AMP-activated protein kinase (AMPK), thereby suppressing mTOR signaling and contributing to the anti-proliferative and anti-inflammatory efficacy of these drugs.

Other names
Bifunctional purine biosynthesis protein ATICAICAR transformylase/inosine monophosphate cyclohydrolaseAICAR transformylase/IMP cyclohydrolasePurHAICARFT/IMPCHase
02

Mechanism of action

Inhibition of the AICAR transformylase activity of ATIC, preventing the conversion of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR/ZMP) to formyl-AICAR (FAICAR). This leads to the accumulation of intracellular ZMP, which acts as an AMP mimetic to allosterically activate AMP-activated protein kinase (AMPK) and inhibit de novo purine synthesis, thereby suppressing cell proliferation and inflammatory pathways.

03

Biological functions

Purine biosynthesisDe novo purine nucleotide biosynthetic processAMPK activationCell proliferationDNA repair
04

Disease associations

CancerInflammationRheumatoid arthritisAICA-ribosiduriaInfection
05

Safety considerations

MyelosuppressionHepatotoxicityGastrointestinal toxicityTeratogenicityNeurological impairment (resembling congenital ATIC deficiency/AICA-ribosiduria)
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Intracellular ZMP accumulationUrinary AICA-riboside excretionAMPK phosphorylationATIC gene polymorphisms (e.g., rs12995526, 347C>G)

Beyond the preview

Go deeper on 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call